Table 3 Association of β-blocker use at discharge and during follow-up with long-term outcomes in a matched cohort
Variables | Control (N = 52) | Always users (N = 52) | Hazard ratio (95% CI) | P value |
|---|---|---|---|---|
All-cause death (n, %) | 32, 61.54% | 42, 80.77% | 2.08(1.18–3.66) | 0.030 |
Refractory heart failure(n, %) | 4, 7.69% | 17, 32.69% | 2.16(1.21–3.87) | 0.003 |
Stroke (n, %) | 13, 25% | 9, 17.31% | 0.63(0.31–1.30) | 0.337 |
Refractory arrhythmia (n, %) | 7, 13.46% | 3, 5.77% | 0.44(0.14–1.42) | 0.183 |
Myocardial infarction (n, %) | 8, 15.38% | 9, 17.31% | 1.41(0.68–2.91) | 0.791 |
Renal failure (n, %) | 0 | 3, 5.77% | 4.55(1.39–14.94) | 0.079 |
Respiratory failure (n, %) | 0 | 1, 1.92% | 6.36(0.84048.19) | 0.315 |